A scalable technology platform capable of producing consistent batches of every human cell has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease.
This webinar discusses
- Today’s challenges in CNS research, disease modelling and drug discovery: limited access to reliable human models.
- How a novel cellular reprogramming technology, opti-ox™, resolves the inconsistency of cellular reprogramming and enables the precise, consistent, and scalable production of human cells.
- The fabrication of synthetic, printed and hybrid materials, and their applications.
- Prof Hagan Bayley | University of Oxford
- Dr Mark Kotter | Founder & CEO bit.bio